6 completed, 3 unknown, 1 active not recruiting, 1 terminated. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 6, Unknown 3, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Cyclosporin A: new trials by email Literature Review of Cyclosporin A trials Research Report on Cyclosporin A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcomes of Patients After Allo-HSCT With Decitabine and NAC decitabine, Acetylcysteine, Semustine - Engraft Failure, Relapse | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 100 | 2021-07-01 | 2021-06-30 |
| A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies Cytarabine, Busulfan, Cyclophosphamide - Leukemia, MDS | Phase 3 | Active not recruiting | First Affiliated Hospital of Zhejiang University | 232 | 2020-09-01 | 2026-04-09 |
| Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema Alitretinoin, cyclosporin A - Hand Eczema | Phase 3 | Unknown | University Medical Center Groningen | 76 | 2017-05-29 | 2019-02-26 |
| Use of Cyclosporin A for the Treatment of Recurrent Miscarriage Cyclosporin A, Dydrogesterone - Miscarriage, Recurrent | Phase 2 / Phase 3 | Unknown | Fudan University | 384 | 2016-05-01 | 2016-03-15 |
| A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP） Cyclosporin A, rhTPO - Immune Thrombocytopenia | Phase 3 | Withdrawn | Shandong University | 2014-07-01 | 2016-04-20 | |
| 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients Everolimus, Tacrolimus, Cyclosporin A - Kidney Transplantation, Renal Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 612 | 2012-12-27 | 2017-05-01 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Completed | Fred Hutchinson Cancer Center | 174 | 2010-11-01 | 2026-04-30 |
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP) - Leukemia, Myeloid, Leukemia | Phase 3 | Terminated | Stanford University | 58 | 2007-08-01 | 2019-09-24 |
| Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia total-body irradiation, allogeneic hematopoietic stem cell transplantation, cyclophosphamide - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder | Phase 3 | Completed | Fred Hutchinson Cancer Center | 25 | 2006-01-01 | 2014-10-31 |
| Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant Cyclosporin A, Belatacept Less Intensive Regimen (LI), Belatacept More Intensive Regimen (MI) - Renal Transplantation | Phase 3 | Completed | Bristol-Myers Squibb | 595 | 2005-02-01 | 2017-07-07 |
| Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) Cyclosporin A, Interferon-alpha2a - Behcet's Disease, Panuveitis | Phase 3 | Completed | University Hospital Tuebingen | 37 | 2004-11-01 | 2018-05-17 |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia filgrastim, asparaginase, cyclophosphamide - Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 3 | Completed | National Cancer Institute (NCI) | 220 | 2002-10-01 | 2014-02-27 |
Leukemia, Myeloid, Acute (3) · Leukemia (2) · Myeloproliferative Disorders (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Abortion, Habitual (1) · Behcet Syndrome (1) · Chromosome 5q Deletion Syndrome (1) · Congenital Abnormalities (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1) · Leukemia, Prolymphocytic (1)
Fred Hutchinson Cancer Center (2) · Bristol-Myers Squibb (1) · First Affiliated Hospital of Zhejiang University (1) · Fudan University (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · Shandong University (1) · Stanford University (1) · The First Affiliated Hospital of Soochow University (1) · University Hospital Tuebingen (1) · University Medical Center Groningen (1)
Germany (5) · United States (5) · China (3) · France (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Hungary (1) · Italy (1)
Bart Scott (1) · Brenda Sandmaier (1) · Dajin Li, MD (1) · Ina Koetter, MD (1) · Kirk Schultz (1) · Ming Hou, Dr. (1) · Robert Lowsky (1) · Yi Luo, MD (1) · Yue Han, Prof. (1)
PMID 22300431, PMID 24831918, PMID 26888217, PMID 29997136, PMID 31248843, PMID 32499241, PMID 33242441, PMID 38993854
P01CA018029 (2), K23HL084054 (1), P01CA078902 (1), P01HL036444 (1), P30CA015704 (1), U10CA098543 (1)